Stratistics MRC¿¡ µû¸£¸é, ¼¼°èÀÇ ³Æ÷ ÀÚ±Ø È£¸£¸ó ½ÃÀåÀº 2025³â 26¾ï ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ µ¿¾È CAGR 6%·Î ¼ºÀåÇØ 2032³â¿¡´Â 39¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
³Æ÷ ÀÚ±Ø È£¸£¸ó(FSH)Àº ³úÇϼöü Àü¿±¿¡ ÀÇÇØ »ý»êµÇ´Â ´ç ´Ü¹éÁú È£¸£¸óÀÔ´Ï´Ù. ¿©¼º¿¡¼´Â ³¼Ò, ³²¼º¿¡¼´Â °íȯÀÇ ¼ºÀå, °³¹ß, ±â´ÉÀ» Á¶ÀýÇÏ¿© »ý½Ä °Ç°¿¡ Áß Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÕ´Ï´Ù. ¿©¼º¿¡¼´Â ³Æ÷ÀÇ ¼º¼÷À» ÀÚ±ØÇÏ°í ³²¼º¿¡¼´Â Á¤ÀÚ Çü¼ºÀ» ÃËÁøÇÕ´Ï´Ù.
2023³â 4¿ù¿¡ °»½ÅµÈ ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¼ºÀÎÀÇ ¾à 6¸í Áß 1¸íÀÌ ºÒÀÓÁõÀ» ¾Î°í ÀÖ½À´Ï´Ù.
ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ Àνİú ¼ö¿ë Áõ°¡
¼¼°èÀÇ ºÒÀÓ·ü Áõ°¡¿Í ü¿Ü¼öÁ¤(IVF) µîÀÇ °íµµ »ý½Ä ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Áö½ÄÀÇ Çâ»óÀ¸·Î È¿°úÀûÀÎ ºÒÀÓ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°Àº ÀνĿ¡ ÀÇÇØ º¸´Ù ¸¹Àº ȯÀÚ°¡ Ä¡·á¸¦ ¹Þ°Ô µÇ¾î, ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, FSHÀÇ »ý»ê ¹× Àü´Þ ¹æ¹ý¿¡ ÀÖ¾î¼ÀÇ ±â¼úÀû Áøº¸°¡ Ä¡·á ¼ºÀûÀ» Çâ»ó½ÃÄÑ, ½ÃÀåÀÇ È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
ºÎÀÛ¿ë°ú ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á
FSH Ä¡·á¿Í °ü·ÃµÈ ºÎÀÛ¿ë°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á´Â ½ÃÀå ¼ºÀåÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. FSH ¿ä¹ýÀ» Æ÷ÇÔÇÑ ºÒÀÓ Ä¡·á¿¡´Â °í¾×ÀÇ ºñ¿ëÀÌ µé±â ¶§¹®¿¡ ƯÈ÷ º¸ÇèÀÌ Àû¿ëµÇÁö ¾Ê´Â Àú¼Òµæ Áö¿ª¿¡¼´Â Á¢±ÙÀÌ Á¦Çѵ˴ϴÙ.
Á¦Ç° Çõ½Å°ú ¹ÙÀÌ¿À½Ã¹Ð·¯
÷´Ü ÀçÁ¶ÇÕ DNA ±â¼ú·Î °³¹ßµÈ ÀçÁ¶ÇÕ FSH Á¦Á¦´Â ¼Òº¯ À¯·¡ È£¸£¸ó¿¡ ºñÇØ ¼øµµ¿Í Àϰü¼ºÀÌ ³ô°í, À¯È¿¼º°ú ¾ÈÀü¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÁ¸®Çʵå ÁÖ»ç±â¿Í Ææ À¯Çü ÁÖ»ç±â¿Í °°Àº ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº ȯÀÚÀÇ ÆíÀǼº°ú ÄÄÇöóÀ̾𽺸¦ Çâ»ó½ÃŰ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í ÀÚ±ØÇÕ´Ï´Ù.
À±¸®Àû¡¤Á¾±³Àû ¿ì·Á
À±¸®Àû, Á¾±³Àû ¿ì·Á´Â FSH ½ÃÀå¿¡ Å« À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·± ¿ì·Á´Â ÀÏ¹Ý ´ëÁßÀÇ ÀνĿ¡ ¿µÇâÀ» ÁÖ¾î Æ¯Á¤ Áö¿ª¿¡¼´Â ±ÔÁ¦¸¦ Á¦ÇÑÇÏ´Â Á¤Ã¥À¸·Î ¿¬°áµÇ¾î ½ÃÀå ħÅõ¸¦ Á¦ÇÑÇÏ°Ô µË´Ï´Ù.
COVID-19ÀÇ À¯ÇàÀº ÁַΠü¿Ü¼öÁ¤(IVF)À» Æ÷ÇÔÇÑ ±ä±Þ¼ºÀÌ ¾ø´Â ºÒÀÓ Ä¡·áÀÇ Áß´ÜÀ» ÅëÇØ FSH ½ÃÀåÀ» È¥¶õ½ÃÄ×°í, ¸¹Àº ³ª¶ó¿¡¼ Æò±Õ 2°³¿ù °¡±î¿î Áö¿¬À» ÀÏÀ¸Ä×½À´Ï´Ù. ¶ÇÇÑ °ø±Þ¸ÁÀÇ Áß´ÜÀ¸·Î ¾à¹°ÀÇ ÀÔ¼ö°¡ ´Ê¾îÁ³½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ÀçÁ¶ÇÕ FSH ºÎ¹®ÀÌ ÃÖ´ë°¡ µÉ Àü¸Á
À¯ÀüÀÚ º¯Çü ¼¼Æ÷ÁÖ¸¦ ÀÌ¿ëÇÑ ÀçÁ¶ÇÕ DNA ±â¼ú¿¡ ÀÇÇØ ´Þ¼ºµÇ´Â ¶Ù¾î³ ¼øµµ, Àϰü¼º, »ý¹°È°¼º¿¡ ÀÇÇØ ÀçÁ¶ÇÕ FSH ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ß»ý ¼ºÀåÀº º¸Á¶»ý½Ä±â¼ú ±â¼ú°ú ºÒÀÓ Ä¡·áÀÇ ¼¼°è µµÀÔ Áõ°¡¿¡ ÀÇÇØ ´õ¿í Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇàÁßÀÎ ¿¬±¸ °³¹ß ³ë·Â¿¡ ÀÇÇØ À¯ÀüÀÚ ÀçÁ¶ÇÕ FSH Á¦Á¦ÀÇ °³·®ÀÌ °è¼ÓµÇ°í ÀÖ¾î, ºÒÀÓ Ä¡·á¿¡ ÀÖ¾î¼ÀÇ ¹Ù¶÷Á÷ÇÑ ¼±ÅÃÀ¸·Î¼ÀÇ ÁöÀ§¸¦ È®°íÇÑ °ÍÀ¸·Î Çϰí, ÃÖ´ë ½ÃÀå Á¡À¯À²¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ÁÖ»çÁ¦ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀÌ ¿¹»óµÈ´Ù.
¿¹Ãø ±â°£ µ¿¾È ³¼Ò Àڱذú °°Àº ºÒÀÓ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ´Â ÁÖ»çÁ¦°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÁÖ»ç±â±¸ÀÇ Áøº¸·Î ȯÀÚÀÇ ÆíÀǼº°ú ÄÄÇöóÀ̾𽺰¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â °í±Þ °Ç° °ü¸® ÀÎÇÁ¶ó, ºÒÀÓ ¹× ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ³ôÀº ÀÎÁöµµ, º¸Á¶»ý½Ä±â¼ú ±â¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ ºÒÀÓÁõÀÇ ³ôÀº À¯º´·ü, ºÒÀÓ Ä¡·á Ŭ¸®´Ð°ú Àü¹®¼¾ÅÍ Áõ°¡µµ °ßÁ¶ÇÑ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº ºÒÀÓ·ü Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, °Ç° °ü¸® ÀÎÇÁ¶ó È®´ë·Î °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇÁ·Î´öƼºê Çコ(»ý½Ä¿¡ °üÇÑ °Ç°)¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀÌ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Follicle stimulating Hormone Market is accounted for $2.6 billion in 2025 and is expected to reach $3.9 billion by 2032 growing at a CAGR of 6% during the forecast period. Follicle Stimulating Hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in reproductive health by regulating the growth, development, and function of the ovaries in females and the testes in males. In women, it stimulates ovarian follicle maturation; in men, it promotes spermatogenesis. FSH levels are often measured to assess fertility, menstrual irregularities, or pituitary function.
According to the World Health Organization (WHO) data updated in April 2023, approximately 1 in 6 adults globally are affected by infertility.
Growing awareness and acceptance of fertility treatments
Increasing infertility rates globally, coupled with enhanced knowledge about advanced reproductive technologies such as IVF, have led to a rising demand for effective fertility solutions. Additionally, expanding healthcare infrastructure, including fertility clinics and specialized centers, supports greater accessibility to FSH therapies. This awareness encourages more patients to seek treatment, driving market growth. Furthermore, technological advancements in FSH production and delivery methods improve treatment outcomes, reinforcing market expansion.
Adverse effects and safety concerns
Adverse effects and safety concerns related to FSH treatments pose challenges to market growth. Some patients experience side effects such as ovarian hyperstimulation syndrome (OHSS), allergic reactions, or hormonal imbalances, which can deter treatment adoption. Moreover, the high cost of fertility treatments, including FSH therapies, restricts access, especially in low-income regions lacking insurance coverage. These safety and financial concerns limit patient willingness and ability to pursue FSH-based fertility interventions, thereby restraining overall market expansion.
Product innovation and biosimilars
Recombinant FSH products, developed through advanced recombinant DNA technology, provide higher purity and consistency compared to urinary-derived hormones, enhancing efficacy and safety. The emergence of biosimilars can reduce treatment costs, making fertility care more affordable and accessible to a broader population. Additionally, innovations in drug delivery systems, such as pre-filled syringes and pen injectors, improve patient convenience and compliance, further stimulating market growth.
Ethical and religious concerns
Ethical and religious concerns present significant threats to the FSH market. Assisted reproductive technologies (ART), including the use of FSH, often face scrutiny related to embryo manipulation, storage, and genetic testing, raising moral and cultural debates. These concerns can influence public perception and lead to restrictive regulatory policies in certain regions, limiting market penetration.
The COVID-19 pandemic disrupted the FSH market primarily through the suspension of non-urgent fertility treatments, including IVF, causing delays averaging nearly two months in many countries. Travel restrictions also limited patient access to fertility clinics, especially for medical tourism. Psychological stress during the pandemic further affected fertility outcomes. Additionally, supply chain interruptions delayed medication availability. However, clinics adapted by implementing safety protocols and offering remote counseling, leading to a gradual recovery in demand as restrictions eased and treatments resumed.
The recombinant FSH segment is expected to be the largest during the forecast period
The recombinant FSH segment is expected to account for the largest market share during the forecast period due to its superior purity, consistency, and bioactivity, achieved through recombinant DNA technology in genetically engineered cell lines. This method minimizes impurities found in urinary-derived FSH, enhancing safety and treatment efficacy. The segment's growth is further supported by increasing adoption of assisted reproductive technologies and infertility treatments worldwide. Moreover, ongoing research and development efforts continue to improve recombinant FSH formulations, solidifying its position as the preferred choice in fertility therapies and contributing to its largest market share.
The injectable segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the injectable segment is predicted to witness the highest growth rate, driven by their widespread use in fertility treatments such as ovarian stimulation. Injectables provide precise dosing and rapid bioavailability, which are critical for effective therapy. Additionally, advancements in injection devices, including pen injectors and pre-filled syringes, enhance patient convenience and compliance. The growing preference for injectable forms over other delivery methods, combined with rising infertility rates and expanding ART adoption, fuels this segment's rapid market growth.
During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, high awareness of infertility and fertility treatments, and favorable reimbursement policies for assisted reproductive technologies. The region benefits from significant investments in biotechnology and pharmaceutical research, resulting in early adoption of innovative FSH therapies. Moreover, a high prevalence of infertility, coupled with a growing number of fertility clinics and specialized centers, drives robust demand.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to increasing infertility rates, rising disposable incomes, and expanding healthcare infrastructure. Growing awareness and acceptance of fertility treatments, along with government initiatives to improve reproductive health, contribute to rising demand. The region's expanding middle class and improvements in assisted reproductive technologies further accelerate market adoption.
Key players in the market
Some of the key players in Follicle stimulating Hormone Market include Ferring Pharmaceuticals, Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Allergan plc, Ipsen Pharma, LG Chem Ltd., Asarina Pharma, Intas Pharmaceuticals Ltd., Bharat Serums and Vaccines Ltd., Sun Pharmaceutical Industries Ltd., Gedeon Richter Plc., Sandoz International GmbH, BioTech Pharmacal, Fuji Pharma Co., Ltd., Lupin Limited, Geneo Pharma, and Fidia Farmaceutici S.p.A.
In May 2024, The National Medical Products Administration (NMPA) in China approved Rekovelle(R), with a commercial launch planned for 2025.
In January 2020, Merck announced that the European Commission had granted Marketing Authorization for a new GONAL-f(R) (follitropin alfa) 150 IU pen. GONAL-f(R) is a recombinant human follicle-stimulating hormone (r-hFSH) used to treat anovulation and to stimulate the development of multiple follicles in women undergoing assisted reproductive technologies (ART).